Catalyst
Slingshot members are tracking this event:
Clovis (CLVS) Expects to Begin Enrolling Patients in Q1 2017 for Phase 1b Combination Study Evaluating Rucaparib with Genentech's (RHHBY) Tecentriq in Solid Tumors and Gynecologic Cancers
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 03, 2017
Occurred Source:
http://phx.corporate-ir.net/phoenix.zhtml?c=247187&p=irol-newsArticle&ID=2269437
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Combination Study, Rucaparib, Tecentriq, Solid Tumors, Gynecologic Cancers, Ovarian Cancer
